Monday, May 23, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

RFI – Development of Animal Models for Antibacterial Drug Development

by Global Biodefense Staff
January 5, 2017
RFI FDA Narrow-Spectrum Antibacterials

RFI FDA Narrow-Spectrum AntibacterialsThe FDA’s Center for Drug Evaluation and Research is seeking input from the public and private sectors on research ideas to facilitate the development of drugs to help mitigate antibiotic resistance.

There is interest in studying therapies for serious bacterial infections that are active against only a single species of bacteria. This is particularly challenging due to rarity of the pathogen of interest, the need to immediately begin antibacterial drug treatment, and the delay in availability of information regarding the antibacterial susceptibility of an isolated pathogen.

FDA is interested in research to advance regulatory science to facilitate the development of narrow-spectrum antibacterial drugs such as those that are active against only a single species of bacteria that may not occur frequently in any one type of infection/site of infection.  When the species occurs infrequently, performing clinical trials can be extremely challenging.  Therefore, animal models of infection may be useful to explore the activity of a candidate antibacterial drug and may help to predict the likelihood of human clinical response.

Additional scientific work to evaluate the current state of animal models of infection and evaluate potential animal models that may predict response in humans could advance the development of antibacterial drugs targeting a single species.

FDA is particularly interested in infections due to Acinetobacter baumanii and Pseudomonas aeruginosa because there are limited therapeutic options to treat some patients with serious infections caused by these bacteria and it is difficult to enroll an adequate number of patients to conduct clinical trials.

Further details are available via Solicitation Number: FDA-RFI-1177696. Responses to this RFI will be accepted until February 1, 2017.

Tags: Animal ModelsRFI

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity
Biosecurity

U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity

April 13, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC